Surmodics, Inc. - Common Stock (SRDX)

Frequently Asked Questions About Surmodics, Inc. - Common Stock (SRDX)

Does Surmodics engage in corporate social responsibility initiatives?

Yes, Surmodics is committed to corporate social responsibility (CSR) initiatives that support community health and wellness. The company often participates in charitable activities, sustainability programs, and educational outreach efforts aimed at promoting healthcare accessibility and patient education, reflecting its dedication to making a positive impact on society.

Does Surmodics pay dividends?

As of my knowledge cutoff date, Surmodics has historically focused on reinvesting in growth and innovation rather than paying dividends. Investors interested in dividend stock opportunities should verify the latest information from official company releases or financial platforms, as policies may change over time depending on the company’s financial situation and strategic goals.

How can investors keep track of Surmodics’ performance?

Investors can track Surmodics’ performance through a variety of avenues, including the company’s Investor Relations website, which provides access to financial reports, press releases, and stock performance data. Additionally, financial news outlets and stock market tracking platforms can offer real-time updates on stock prices and performance trends related to SRDX.

How does Surmodics ensure product quality?

Surmodics ensures product quality through rigorous compliance with regulatory standards and a robust quality management system. The company conducts thorough testing and validation processes for its products, adheres to relevant guidelines, and fosters a culture of continuous improvement to maintain high standards of safety and efficacy in all its offerings.

How does Surmodics innovate in medical technology?

Surmodics fosters innovation through robust research and development efforts, collaborating closely with healthcare partners to identify unmet medical needs. By investing in emerging technologies and expanding its product portfolio, Surmodics aims to bring ground-breaking solutions to market that improve the efficacy and safety of medical treatments.

How does Surmodics prioritize customer feedback?

Surmodics prioritizes customer feedback as a vital part of its product development and improvement processes. The company engages with healthcare professionals, partners, and end-users to gather insights and experiences, using this valuable input to refine its offerings and ensure that its products effectively address the real-world challenges faced in clinical settings.

Is Surmodics involved in partnerships or collaborations?

Yes, Surmodics actively pursues partnerships and collaborations with other healthcare organizations, research institutions, and technology companies. These collaborations can help accelerate product development, expand market reach, and enhance the company's innovative capabilities, ultimately contributing to improved patient care and medical outcomes.

What are some challenges that Surmodics faces?

Surmodics, like many companies in the medical technology field, faces several challenges, including intense competition, the need for continuous innovation, regulatory hurdles, and market volatility. Additionally, economic conditions and changes in healthcare policies may affect the demand for its products, requiring the company to remain agile and responsive to maintain its market position.

What are the main product lines of Surmodics?

Surmodics, Inc. operates primarily in two segments: Medical Device and In Vitro Diagnostics. Within the Medical Device segment, Surmodics develops and manufactures products such as drug-coated balloons, catheter coatings, and stent delivery systems. The In Vitro Diagnostics segment includes diagnostic assays and coating technologies that improve the performance of diagnostic devices and biosensors.

What does Surmodics, Inc. do?

Surmodics, Inc. is a leading provider of medical device and in vitro diagnostic technologies. The company focuses on advancing medical innovation by offering a broad range of products, including drug-coated balloon catheters and specialized coatings for medical devices. Surmodics collaborates with partners to improve patient outcomes through cutting-edge technology in the fields of cardiovascular, ophthalmology, and other medical applications.

What financial information is available for Surmodics?

Surmodics provides regular financial updates, including quarterly earnings reports and annual financial statements, which detail its revenue, expenses, net income, and other key financial metrics. This information is available to investors and the public on its website and through regulatory filings, helping stakeholders assess the company's financial health and performance.

What is Surmodics’ competitive advantage?

Surmodics’ competitive advantage lies in its extensive expertise in medical coatings and diverse product portfolio that meets various clinical needs. The company’s strong commitment to research and development, coupled with its focus on quality and regulatory compliance, allows it to deliver innovative products that set it apart from competitors and resonate with healthcare providers.

What is Surmodics’ growth strategy?

Surmodics' growth strategy focuses on innovation, strategic partnerships, and expanding its market presence in key healthcare sectors. By investing in research and development, conducting clinical studies, and enhancing customer relationships, the company aims to launch new products and services that meet evolving patient and provider needs, thereby driving sustainable long-term growth.

What is Surmodics’ mission statement?

Surmodics’ mission is to advance medical innovation and improve patient outcomes by delivering high-quality, reliable medical technology solutions. The company emphasizes a commitment to developing technologies that address critical healthcare needs, ensuring that its products have a meaningful impact on the lives of patients and healthcare providers alike.

What markets does Surmodics operate in?

Surmodics operates mainly in the global healthcare markets, specifically targeting the cardiovascular, ophthalmology, and in vitro diagnostics sectors. The company’s products are used in hospitals and healthcare facilities across the world, providing essential tools that contribute to effective medical interventions and patient care.

What recent developments has Surmodics announced?

Surmodics frequently updates its stakeholders about significant advancements through press releases. Recent developments may include new product launches, clinical trial results, regulatory approvals, and strategic partnerships aimed at enhancing its product offerings and market presence. Keeping an eye on these announcements provides insights into the company's growth trajectory.

What stock exchange is Surmodics, Inc. listed on?

Surmodics, Inc. is listed on the Nasdaq stock exchange under the ticker symbol SRDX. Being a publicly traded company, Surmodics' stock is available for purchase on the open market, allowing investors to become stakeholders in its continued growth and success in the medical technology sector.

When was Surmodics, Inc. founded?

Surmodics, Inc. was founded in 1979. The establishment of the company marked the beginning of its commitment to developing innovative medical technologies that enhance patient care. Over the years, Surmodics has evolved significantly, continually expanding its product offerings and market reach in response to the growing demands of the healthcare industry.

Where is Surmodics headquartered?

Surmodics, Inc. is headquartered in Eden Prairie, Minnesota, USA. This location places the company in a vibrant healthcare and technology ecosystem, allowing it to collaborate with other innovators and institutions in the medical field while accessing a skilled workforce to drive its business operations.

Who are the key executives at Surmodics, Inc.?

The executive leadership team at Surmodics, Inc. includes a diverse group of professionals with extensive experience in the medical technology industry. This team typically comprises the Chief Executive Officer, Chief Financial Officer, Chief Operating Officer, and heads of various departments. Their combined expertise drives the company's strategic direction and ensures operational excellence.

What is the current price of Surmodics, Inc. - Common Stock?

The current price of Surmodics, Inc. - Common Stock is 29.27

When was Surmodics, Inc. - Common Stock last traded?

The last trade of Surmodics, Inc. - Common Stock was at 2:55 pm EDT on April 4th, 2025

What is the market capitalization of Surmodics, Inc. - Common Stock?

The market capitalization of Surmodics, Inc. - Common Stock is 413.70M

How many shares of Surmodics, Inc. - Common Stock are outstanding?

Surmodics, Inc. - Common Stock has 14.13M shares outstanding.